glp-1 lean mass loss Balancing weight and muscle in GLP1 receptor agonist therapy Weight loss and muscle building

Until further evidence is provided, GLP-1 RAs will likely be used preferentially in patients with cardiovascular disease or cardiovascular risk factors

Specific medication guides for early dosing Each GLP-1 medication has its own characteristics that affect early dosing decisions

Symptoms of hypoglycaemia (low blood sugar) such as sweating, dizziness, confusion, or shakiness require immediate attention, especially if you are taking insulin or sulfonylurea medications alongside Wegovy, as these combinations increase hypoglycaemia risk

6 However, liraglutide has been the main drug in this class linked to skin reactions, with cases of exanthematous pustulosis in photo exposed areas, generalized erythematous plaques and nodules, and pruriginous macules at the injection site reported in the literature

The two medications have completely separate dosing schedules, different escalation increments, and different maximum doses